

# Haem.io

Use of Funds - Seed Investment

## Executive Summary

### TOTAL INVESTMENT

**£750,000**

Seed Round

### RUNWAY

**18  
Months**

To Series A readiness

### KEY MILESTONE

**UKCA +  
Pilots**

4 NHS validations  
complete

### Investment Purpose

This £750k seed investment provides an 18-month runway to achieve UKCA certification as a Class IIb medical device, complete 4 NHS pilot study validations, and secure first commercial contracts. These milestones position Haem.io for a successful Series A fundraising round (£2M-£3M) in Q2-Q3 2027, with a target valuation of £8M-£12M pre-money.

# Detailed Use of Funds Breakdown

## 1. Team & Personnel (48% - £360,000)

<b>Founder &amp; Engineer</b>	<b>£165,000</b>
-------------------------------	-----------------

*Full-time founder salary and engineering work (18 months)*

<b>Compliance Officer</b>	<b>£105,000</b>
---------------------------	-----------------

*Regulatory affairs specialist for UKCA certification process (18 months)*

<b>Clinical Validation Lead</b>	<b>£90,000</b>
---------------------------------	----------------

*Manages NHS pilot studies, clinical validation, and data collection (18 months)*

**Subtotal: £360,000**

**Rationale:** Our team structure balances technical development (founder engineer), regulatory expertise (compliance officer), and clinical validation (clinical lead). This ensures we can simultaneously progress UKCA certification while running NHS pilot studies and maintaining platform development.

## 2. Regulatory & Clinical Validation (24% - £180,000)

<b>UKCA Certification</b>	<b>£100,000</b>
---------------------------	-----------------

*Notified body fees, technical file preparation, clinical evaluation, performance studies, audit costs*

<b>4 NHS Pilot Studies</b>	<b>£80,000</b>
----------------------------	----------------

*Manchester Foundation Trust, The Christie NHS, Royal Devon & Exeter, UK AML Research Network  
(coordination, data collection, validation reports)*

**Subtotal: £180,000**

**Rationale:** UKCA certification is the critical regulatory milestone that enables commercial sales. The 4 NHS pilot studies provide clinical validation data and establish relationships with key NHS trusts, creating a pipeline for post-certification sales. Both are essential for Series A readiness.

### 3. Infrastructure & Operations (28% - £210,000)

**Cloud & AI Compute** **£15,000**

*AWS/Azure infrastructure, LLM API costs, data storage, development environments (18 months)*

**Legal & Accounting** **£25,000**

*Corporate legal, contract review, accounting services, tax compliance, SEIS/EIS advance assurance*

**Insurance & Professional Fees** **£15,000**

*Professional indemnity insurance, medical device liability insurance, professional advisors*

**Office & Equipment** **£20,000**

*Co-working space, laptops, development hardware, office supplies*

**Marketing & Business Development** **£15,000**

*Conference attendance, NHS trust presentations, investor materials, website, branding*

**Contingency Buffer** **£120,000**

*24% buffer for unexpected costs, regulatory delays, or scope changes*

**Subtotal: £210,000**

**Rationale:** Infrastructure costs are kept lean with cloud-based development. The 24% contingency buffer provides essential flexibility for regulatory timelines (which can vary), unexpected pilot study requirements, or NHS administrative delays. This buffer ensures we can complete all milestones even if timelines extend slightly.

# 18-Month Timeline & Milestones

---

- Q1 2026**    **Foundation Phase:** Team hiring begins (Compliance Officer, Clinical Validation Lead), regulatory strategy finalization, initial UKCA documentation preparation. Monthly burn: £50k.
- 
- Q2 2026**    **Team Complete:** All team members onboarded (4 founders + 2 hires). UKCA prep & documentation in full swing. NHS pilot study agreements finalized. Monthly burn: £50k.
- 
- Q3 2026**    **Pilot Launch:** NHS pilot studies launch across 4 sites. UKCA certification process formally begins with notified body engagement. Technical documentation complete. Monthly burn: £40k.
- 
- Q4 2026**    **UKCA Submission:** UKCA technical file submitted to notified body. Pilot studies data collection ongoing. Initial clinical validation results emerging. Monthly burn: £40k. Cash remaining: £210k.
- 
- Q1 2027**    **Certification Progress:** UKCA certification in progress (audit phase). Pilot studies wrap-up and data analysis. Clinical validation reports prepared. Monthly burn: £35k. Cash remaining: £105k.
- 
- Q2 2027**    **Milestone Achievement: UKCA certification received.** Pilot validation reports published. **Series A fundraising begins (£2M-£3M target).** Cash reaches £0 → Series A closes to fund next phase.
- 

## Key Milestones at 18 Months

---

### Series A Readiness Criteria

- ✓ **UKCA certification complete** - Enables commercial sales
- ✓ **4 NHS pilot validations published** - Clinical proof of concept
- ✓ **First 2-3 contracts signed** - Commercial validation (Q4 2027)
- ✓ **Team proven** - Regulatory, clinical, and technical capabilities demonstrated
- ✓ **Clear path to revenue** - Contracts signed, revenue recognition begins Q1 2028

These milestones position Haem.io for a successful Series A fundraising round with significantly de-risked commercial and regulatory pathways. The combination of regulatory approval, clinical validation, and signed contracts demonstrates both product-market fit and execution capability.

# Burn Rate Analysis

Phase	Months	Monthly Burn	Quarterly Spend	Cumulative Spend
Foundation	Q1-Q2 2026	£50k	£150k	£300k
Pilot & Certification	Q3-Q4 2026	£40k	£120k	£540k
Final Push	Q1-Q2 2027	£35k	£105k	£645k
Contingency	Buffer	—	—	£105k remaining

**Note:** Burn rate decreases over time as one-time costs (UKCA certification, pilot setup) are front-loaded. The variable burn rate reflects this phased approach, with higher costs in early quarters for team onboarding and regulatory setup, then decreasing as processes mature.

## Risk Mitigation & Contingency

### Contingency Buffer Usage (24% - £120k)

The £120k contingency buffer provides flexibility for:

- **Regulatory timeline delays:** UKCA certification can take longer than expected if notified body requires additional evidence or clarification
- **Pilot study scope changes:** NHS trusts may request additional validation endpoints or extended study periods
- **NHS administrative delays:** Contract negotiations or pilot study approvals may take longer than anticipated
- **Unexpected technical requirements:** Additional security audits, data residency requirements, or integration needs
- **Team scaling needs:** If we need to accelerate hiring or bring in specialist consultants

**Contingency Management:** We will track contingency usage monthly and report to investors. Any unused contingency at 18 months will extend runway or accelerate Series A milestones.

## Post-Seed: Series A Readiness

---

Upon completion of the 18-month seed runway, Haem.io will be positioned for Series A fundraising with:

- **Regulatory approval:** UKCA certification enables immediate commercial sales
- **Clinical validation:** 4 NHS pilot studies provide proof of clinical utility and safety
- **Commercial traction:** First contracts signed (Q4 2027), revenue recognition beginning Q1 2028
- **Proven team:** Demonstrated ability to execute on regulatory, clinical, and commercial milestones
- **Clear growth path:** Pipeline of NHS trusts, ancillary revenue streams (diagnostic desk, treatment tools), and international expansion opportunities

**Series A Target:** £2M-£3M in Q2-Q3 2027, at a valuation of £8M-£12M pre-money. Funds will be used for sales team expansion, international expansion (EU, Middle East), and product development (additional blood cancer types, treatment response tools).

---

### Haem.io Ltd

Company Number 16528517

73 Meliden Road, Prestatyn, LL19 8RH, United Kingdom

*This use of funds breakdown is based on current regulatory timelines, NHS pilot study requirements, and conservative cost estimates. Actual spending may vary based on execution speed and market conditions.*